Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction
| Autor: | Rajesh Kumar Suman, Manjusha K. Borde, Ipseeta Ray Mohanty, Ujwala Maheshwari, Y.A. Deshmukh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Journal of Clinical and Diagnostic Research, Vol 10, Iss 3, Pp FF13-FF18 (2016) |
| Druh dokumentu: | article |
| ISSN: | 2249-782X 0973-709X |
| DOI: | 10.7860/JCDR/2016/15794.7459 |
| Popis: | Introduction: Berberine, an isoquinoline alkaloid isolated from the Berberis aristata, has been shown to display a wide array of pharmacological activities (hypoglycaemic and hypolipidemic). Aim: The present study was designed to investigate whether these pharmacological properties translate into the cardioprotective effects of Berberine in the setting of diabetes mellitus. Materials and Methods: Necessary approval from the Institutional Animal Ethics Committee was taken for the study. Experimental diabetes was produced with single dose of Streptozotocin (STZ): 45mg/kg ip and myocardial infarction was induced by administering Isoproterenol (ISP): 85mg/kg, sc to rats on 35th & 36th day. After the confirmation of diabetes on 7th day (>200mg/dl), Berberine (100 mg/kg) was administered orally to experimental rats from day 8 and continued for 30 days thereafter. Various anti-diabetic (Glucose, HbA1c), cardioprotective (CPK-MB), metabolic (lipid profile), safety {liver function (SGPT, kidney function (Creatinine)} and histopathological indices of injury were evaluated in Healthy Control, Diabetic Control and Berberine treated groups. Results: Administration of STZ-ISP resulted in a significant decrease in body weight (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|